LEADER 01875nam  2200445   450 
001 9910830570403321
005 20210114143130.0
010   $a1-119-48703-X
010   $a1-5231-3729-0
010   $a1-119-48702-1
010   $a1-119-48704-8
035   $a(CKB)4100000010870908
035   $a(MiAaPQ)EBC6317478
035   $a(PPN)255094981
035   $a(OCoLC)1159650070
035   $a(EXLCZ)994100000010870908
100   $a20210114d2021      uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aApplied biocatalysis $ethe chemist's enzyme toolbox /$fedited by John Whittall, Peter W. Sutton
210  1$aHoboken, New Jersey ;$aChichester, West Sussex, England :$cWiley,$d[2021]
210  4$dİ2021
215   $a1 online resource (xviii, 540 pages) $cillustrations
311   $a1-119-48701-3 
330   $a"Biocatalysis has had a significant impact on the synthesis of active pharmaceutical ingredients (APIs) in recent years. The main driver for this is the ability to harness the regio- and stereoselectivity of enzymes to improve the efficiency of synthetic routes. For example, enzymes can offer direct access to enantiopure products, where traditional organic synthesis would require either resolution or the use of auxiliary groups [1], whilst applied enzymes have improved syntheses or generated molecules that would otherwise be either impossible or impractical to synthesise."--$cProvided by publisher.
606   $aBiocatalysis
615  0$aBiocatalysis.
676   $a660.2995
702   $aWhittall$b John
702   $aSutton$b Peter$g(Peter W.),
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910830570403321
996   $aApplied biocatalysis$94085322
997   $aUNINA